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Efficacy of renal denervation is positively impacted by longitudinal treatments
Meital Mazor1
1VESSIX VASCULAR, Laguna Hills, CA
Background: Catheter-based percutaneous renal denervation (RDN) has shown durable
reductions of blood pressure in patients with uncontrolled hypertension. The importance
of applying circumferential denervations inside the renal arteries is known to contribute to
efficacy; however, the significance of denervations along the entire renal artery length is
yet to be appreciated.
Methods: We used the V2 System™ (Vessix Vascular Inc., Laguna Hills, CA) for the
renal denervation procedures. The V2 System consists of a proprietary bipolar RF
generator and an over-the-wire low pressure balloon catheter with an array of radiofre-
quency (RF) electrodes mounted on the exterior in an offset helical pattern. Each
temperature controlled dose (68°C) of bipolar energy is delivered for 30 seconds. A total
of 15 juvenile Yorkshire swine were treated bilaterally (n3 in each group, see table).
Efficacy was evaluated at 14 days post treatment using an HPLC-MS/MS method to
measure kidney tissue norepinephrine (NEPI). In addition, histopathologic methods were
used to assess the percentage of affected nerves.
Results: A single V2 treatment per artery with 95% circumferential coverage and 60%
length coverage (21 mm) was applied resulting in 40% of nerves being affected and a
NEPI reduction of 46% when compared to control group endogenous level. Increasing the
circumferential coverage by 35% did not change efficacy. However, increasing coverage
length by 40% significantly increased NEPI reduction to 78% and significantly increased
the percentage of affected nerves to 58% (p0.05) and was comparable to surgical
denervation.
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Single V2
treatment
One treatment per artery
(each electrode  4 mm
long and 2.5 mm wide)
95% 60% 322331 46% 40%11
V2 treatments
of full artery
length
Up to 2 treatments in
order to treat the entire
length of the artery
(proximal treatment
could be partial, with only
a few RF electrodes
activated)
95% 100% 132191 78% 58%17
Single V2
treatment
using balloon
with
horizontal RF
electrodes
Electrodes were
positioned in an
horizontal pattern in
order to increase
circumferential coverage
(each electrode is 2.5
mm long and 4 mm
wide)
130% 60% 356321 41% 37%14
Surgical
denervation
Adventitia was separated
along the entire length of
the artery and renal
nerves removed
100% 100% 154285 75% NA
Untreated
Sham control
Interventional procedure,
without renal denervation
treatment.
0% 0% 60161 0% 0%
Conclusions: Longitudinal denervations of the renal artery, in addition to circumferential
denervations during RDN procedures, results in greater efficacy. The Vessix V2 Renal
Denervation System may offer advantages since it allows for both longitudinal and
circumferential denervations with short treatment duration.
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Renal Sympathetic Denervation - Inducing An Instantaneous And Persisting
24h Ambulatory Blood Pressure Drop In Patients With Resistant
Hypertension – Results From The Halle-RDN-Registry
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Maria Leuthold1, Silke Markau1, Uwe Raaz2, Therese Schubert1, Alexander Vogt1,
Karl Werdan1
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Background: Catheter-based renal sympathetic denervation (RDN) has proved to
significantly reduce blood pressure (BP) in patients with resistant hypertension. So far,
current available data are almost entirely derived from office-based blood pressure
measurements (OBPM) with only few data relying on 24h ambulatory blood pressure
monitoring (ABPM). However, ABPM is commonly regarded as a much more reliable
method and therefore a better approach to evaluate the effects of RDN.
Methods: Our study carefully investigated the early and subsequent blood pressure
response to RDN in a cohort of 120 consecutive patients with resistant hypertension
(systolic BP 150 mm Hg on 3 antihypertensive drugs). Baseline values included a
mean age of 64.59 years, 48% women, 45% diabetic, 18% coronary artery disease and
5.7 1.5 antihypertensive medications. A 24h Holter BP monitoring was recorded in
every patient 24h before as well as 24h, 3 and 6 months after RDN. BP readings were then
averaged according to daytime (7:00am-22:00pm), nighttime (22:00pm-7:00am) and 24
hours intervals. All data were statistically analysed with repeated measures ANOVA and
Greenhouse-Geisser correction if indicated.
Results: In treated patients mean averaged systolic 24h BP was reduced by 9.681.59
mmHg (p0.001; n 120) during the first 24 hours. Systolic blood pressure reduction
appeared to be much higher at daytime (12.11.63 mm HG; p0.001) compared to
nighttime (4.41.79 mm Hg; p0.016) which might indicate the role of sympathetic
activity at daytime. A concordant effect on diastolic BP was observed: 5.90.88 mmHg
(p0.001). Systolic BP reduction sustained at 3 (6.31.84 mm Hg, p0.005, n 74) and
6 months (6.73.0 mm Hg, p0,201, n 38) without further decrease.
Conclusions: In patients with resistant hypertension, catheter-based RDN results in an
immediate and persisting reduction of systolic and diastolic ABPM. Compared to
office-based data ABPM effects are expectedly less pronounced. Our analysis did not
confirm the so far described gradual drop in BP up to 6 months. On the contrary a slight
non-significant compensation of BP reduction was observed after the initial drop between
day one and the 3 as well as 6 months follow-ups.
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Background: Renal denervation (RDN) using low power radiofrequency energy has
been shown to substantially reduce blood pressure (BP) in patients with treatment-
resistant hypertension. Documentation of duration of antihypertensive effects and the
potential for late development of adverse events is important for determining proper
positioning of this therapy.
Methods: Symplicity HTN-1 is an open-label cohort study which enrolled 153 patients
with systolic BP 160 mm Hg while taking 3 antihypertensive drugs at optimal
dosages, including a diuretic. Patients were followed semi-annually to 3 years post-RDN.
Changes in office-based BP, changes in distribution of BP measurements, renal function,
electrolytes, and medication usage were monitored through 3 years follow-up. Systolic BP
(SBP) reductions of 10 mmHg or more were determined at 1 month and the rates of
delayed response thereafter were calculated.
Results: 114 patients have been followed through 2 years post-RDN and 34 patients for
3 years. Mean age at baseline was 5711 years; 39% of patients were female; 31% had
type 2 diabetes mellitus; eGFR was 8320 mL/min and BP was 175/9817/15 mmHg.
Mean SBP change post-RDN was 32.7  18.4 mmHg at 2 years and 33.1  13.3
mmHg at 3 years. A SBP drop 10 mmHg occurred in 69% of patients at 1 month, and
of the patients with10 mmHg drop in SBP at 1 month 64%, 82%, and 100% responded
with a reduction in SBP 10 mmHg at 1, 2, and 3 years, respectively. There was one
progression of a pre-existing renal artery stenosis and 3 deaths 2.0% unrelated to the
device or therapy.
Conclusions: RDN results in a significant and durable reduction of SBP in patients with
treatment-resistant hypertension. Patients with minimal initial reduction in BP may have
significant reductions later which are not explained by medication changes. Safety and
efficacy data on a larger cohort of patients with 2 and 3 year follow-up will be presented.
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Renal resistive indices, urinary albumin excretion and renal function in
patients with resistant hypertension after catheter-based renal sympathetic
denervation
Felix Mahfoud1, Bodo Cremers1, Christian Ukena1, Henry Krum2, Paul Sobotka3,
Markus Schlaich4, Bruno Scheller5, Ulrich Laufs1, Michael Böhm1
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Background: Increased renal resistive index (RRI) and urinary albumin excretion (UAE)
are markers of hypertensive end-organ damage. Increased sympathetic activity is a main
contributor to the pathophysiology. Catheter-based renal sympathetic denervation (RD)
offers a new interventional approach to reduce renal sympathetic activity and blood
pressure in resistant hypertension. The influence of RD on renal hemodynamics, renal
function, and UAE in patients with resistant hypertension has not been studied.
Methods: One hundred consecutive patients with resistant hypertension were included in
the study. 88 underwent interventional RD and 12 served as controls. Systolic, diastolic
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